Behind a personalized therapy with immune check-point inhibitors in metastatic bladder cancer: ready for a primetime?
作者信息
Poletajew Sławomir, Krajewski Wojciech, Kryst Piotr
机构信息
Second Department of Urology, Centre of Postgraduate Medical Education, Warsaw, Poland.
Department of Urology and Oncological Urology, Wrocław Medical University, Wrocław, Poland.
出版信息
Transl Androl Urol. 2020 Dec;9(6):2479-2482. doi: 10.21037/tau-20-907.
Abstract
摘要
相似文献
1
Behind a personalized therapy with immune check-point inhibitors in metastatic bladder cancer: ready for a primetime?转移性膀胱癌中免疫检查点抑制剂个性化治疗的背后：准备好迎来黄金时代了吗？
Transl Androl Urol. 2020 Dec;9(6):2479-2482. doi: 10.21037/tau-20-907.
2
New imaging techniques for non-muscle invasive bladder cancer: ready for primetime.新型影像技术在非肌肉浸润性膀胱癌中的应用：时机已成熟。
Urol Clin North Am. 2013 May;40(2):271-9. doi: 10.1016/j.ucl.2013.01.014. Epub 2013 Mar 7.
3
Bladder cancer: molecular determinants of personalized therapy.膀胱癌：个性化治疗的分子决定因素
Curr Drug Targets. 2015;16(2):115-24. doi: 10.2174/1389450116666150204115756.
4
Immune check-point in endometrial cancer.子宫内膜癌的免疫检查点。
Int J Clin Oncol. 2019 Aug;24(8):910-916. doi: 10.1007/s10147-019-01437-7. Epub 2019 May 2.
5
New Approaches in Glioblastoma Multiforme: The Potential Role of Immune- check Point Inhibitors.多形性胶质母细胞瘤的新方法：免疫检查点抑制剂的潜在作用
Curr Cancer Drug Targets. 2017;17(3):282-289. doi: 10.2174/1568009616666160813183738.
6
Ultrabrief delirium assessments--are they ready for primetime?超简短谵妄评估——它们准备好进入黄金时段了吗？
J Hosp Med. 2015 Oct;10(10):694-5. doi: 10.1002/jhm.2478. Epub 2015 Sep 16.
7
Immunotherapy for bladder cancer.膀胱癌的免疫疗法。
Res Rep Urol. 2015 May 4;7:65-79. doi: 10.2147/RRU.S63447. eCollection 2015.
8
Expected Paradigm Shift in Brain Metastases Therapy-Immune Checkpoint Inhibitors.脑转移瘤治疗的预期范式转变——免疫检查点抑制剂。
Mol Neurobiol. 2018 Aug;55(8):7072-7078. doi: 10.1007/s12035-018-0905-3. Epub 2018 Jan 30.
9
Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemoradiotherapy before surgery in patients with locally advanced rectal cancer: is it ready for primetime?循环游离DNA作为局部晚期直肠癌患者术前新辅助放化疗后治疗失败的预测指标：它已准备好成为主流了吗？
Ann Oncol. 2018 Mar 1;29(3):532-534. doi: 10.1093/annonc/mdy043.
10
The current status of checkpoint inhibitors in metastatic bladder cancer.检查点抑制剂在转移性膀胱癌中的现状
Clin Exp Metastasis. 2016 Oct;33(7):629-35. doi: 10.1007/s10585-016-9807-9. Epub 2016 Jul 5.
引用本文的文献
1
Effects of Different Organ Metastases on the Prognosis of Stage IV Urothelial Carcinoma of the Bladder.不同器官转移对IV期膀胱尿路上皮癌预后的影响
J Oncol. 2022 Nov 2;2022:8594022. doi: 10.1155/2022/8594022. eCollection 2022.
本文引用的文献
1
PD-L1 assessment in urothelial carcinoma: a practical approach.尿路上皮癌中PD-L1的评估：一种实用方法。
Ann Transl Med. 2019 Nov;7(22):690. doi: 10.21037/atm.2019.10.24.
2
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort: Under the Auspices of the EAU-ESMO Guidelines Committees.EAU-ESMO 共识声明：晚期和变异型膀胱癌的管理——一项国际协作多方利益相关者的努力：在 EAU-ESMO 指南委员会的支持下。
Eur Urol. 2020 Feb;77(2):223-250. doi: 10.1016/j.eururo.2019.09.035. Epub 2019 Nov 19.
3
A meta-analysis of the efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors as treatments for metastatic bladder cancer.PD-1/PD-L1免疫检查点抑制剂治疗转移性膀胱癌的疗效和安全性的荟萃分析。
Onco Targets Ther. 2019 Mar 4;12:1791-1801. doi: 10.2147/OTT.S186271. eCollection 2019.
4
Unusual radiologic manifestation of pseudoprogression in pulmonary metastases after durvalumab treatment in metastatic bladder urothelial cancer.转移性膀胱癌肺转移患者在接受 durvalumab 治疗后出现假性进展的不寻常影像学表现。
Thorac Cancer. 2019 Apr;10(4):1016-1018. doi: 10.1111/1759-7714.12994. Epub 2019 Feb 7.
5
Evaluation of PD-L1 biomarker for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatments for urothelial carcinoma patients: A meta-analysis.评估 PD-L1 生物标志物在免疫检查点抑制剂（PD-1/PD-L1 抑制剂）治疗尿路上皮癌患者中的作用：一项荟萃分析。
Int Immunopharmacol. 2019 Feb;67:378-385. doi: 10.1016/j.intimp.2018.12.018. Epub 2018 Dec 22.
6
Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer.Zr-atezolizumab 成像作为一种非侵入性方法，用于评估 PD-L1 阻断在癌症中的临床反应。
Nat Med. 2018 Dec;24(12):1852-1858. doi: 10.1038/s41591-018-0255-8. Epub 2018 Nov 26.
7
Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma.在转移性黑色素瘤中对免疫检查点阻断治疗反应的稳健预测。
Nat Med. 2018 Oct;24(10):1545-1549. doi: 10.1038/s41591-018-0157-9. Epub 2018 Aug 20.
8
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab.基于血液的肿瘤突变负担可预测接受阿替利珠单抗治疗的非小细胞肺癌患者的临床获益。
Nat Med. 2018 Sep;24(9):1441-1448. doi: 10.1038/s41591-018-0134-3. Epub 2018 Aug 6.
9
TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas.基于结直肠癌中肿瘤程序性死亡受体配体1（PD-L1）表达状态和肿瘤浸润淋巴细胞的TIME（肿瘤微环境中的肿瘤免疫）分类
Oncoimmunology. 2018 Mar 19;7(7):e1442999. doi: 10.1080/2162402X.2018.1442999. eCollection 2018.
10
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.肿瘤突变负担与纳武利尤单抗单药治疗及联合伊匹单抗治疗小细胞肺癌的疗效。
Cancer Cell. 2018 May 14;33(5):853-861.e4. doi: 10.1016/j.ccell.2018.04.001. Epub 2018 May 3.
Zotero 插件